FDA regulatory submissions get rejected most often because of incomplete or inconsistent data, deficiencies in Chemistry, Manufacturing, and Controls (CMC) documentation, or clinical packages that fail to demonstrate sufficient safety and efficacy. Rejection does not always mean a product is unviable — it typically means the submission did not meet the FDA’s evidentiary standards at that point in time. The sections below break down the most common causes of rejection and what companies can do to avoid them.
What happens after the FDA rejects a submission?
When the FDA rejects a submission, it issues a Complete Response Letter (CRL) outlining the specific deficiencies that must be addressed before the application can be approved. A CRL does not close the door on approval — it is a formal request for additional information, corrections, or new data. The applicant must then decide whether to resubmit, request a meeting with the FDA, or withdraw the application entirely.
The CRL will categorize issues by severity and type, ranging from minor labeling corrections to major requests for new clinical trials. Depending on the nature of the deficiencies, a resubmission classified as a Class 1 response is reviewed within two months, while a Class 2 response — which involves more substantial new data — is reviewed within six months. Understanding exactly what the FDA is asking for, and why, is the most important step before planning any resubmission strategy.
What are the most common reasons FDA submissions get rejected?
The most common reasons FDA submissions are rejected include CMC deficiencies, inadequate clinical evidence, statistical analysis failures, insufficient safety data, and poor application organization. Regulatory submissions that lack consistency between modules, contain gaps in manufacturing validation data, or present clinical results that do not clearly support the proposed indication are the most frequent targets for CRLs.
Beyond the technical content, procedural missteps also contribute to rejection. These include failing to respond adequately to prior FDA feedback, submitting outdated reference standards, or neglecting to align the submission with the most current FDA guidance documents. The FDA evaluates both the quality of the science and the completeness of the regulatory package, and weaknesses in either area can lead to a refusal to file or a full rejection after review. If you are unsure whether your submission strategy is aligned with current expectations, explore our regulatory services to see how we can help.
- CMC deficiencies: Incomplete manufacturing data, unvalidated processes, or inconsistent specifications
- Clinical data gaps: Insufficient evidence of efficacy or an inadequately characterized safety profile
- Statistical issues: Poorly defined endpoints, underpowered studies, or flawed analytical methods
- Labeling problems: Proposed labeling that does not align with clinical findings
- Organizational deficiencies: Missing sections, inconsistent cross-references, or non-eCTD-compliant formatting
How do CMC deficiencies lead to FDA rejection?
CMC deficiencies lead to FDA rejection when the submission fails to demonstrate that the drug product can be consistently manufactured to the required quality standards. The FDA needs confidence that every batch will be safe, pure, and potent — and if the CMC section cannot establish that, the application will not advance to approval regardless of how strong the clinical data may be.
Common CMC failures include incomplete process validation data, inadequately characterized reference standards, insufficient stability data to support the proposed shelf life, and poorly defined control strategies for critical quality attributes. For biologics and complex molecules, the bar is particularly high — the FDA expects a thorough understanding of the relationship between manufacturing process parameters and product quality.
Sponsors often underestimate the depth of CMC documentation the FDA requires. A manufacturing process that works reliably in practice still needs to be documented, validated, and described in a way that gives the reviewer full confidence in its reproducibility. Gaps in this area are among the leading causes of preventable rejection in regulatory submissions.
Why do clinical data packages fail to meet FDA standards?
Clinical data packages fail to meet FDA standards when they do not provide sufficient, well-controlled evidence that the product is safe and effective for its intended use. The most frequent failures involve inadequate trial design, endpoints that do not align with what the FDA considers clinically meaningful, or safety databases that are too small to characterize the risk profile of the product.
A common pitfall is designing a pivotal trial without early alignment with the FDA on the primary endpoint. What a sponsor considers a reasonable measure of efficacy may not match what the FDA will accept as a basis for approval. This is precisely why Pre-NDA and End-of-Phase 2 meetings exist — to resolve these questions before pivotal data is generated, not after.
Other frequent clinical data failures include:
- Inadequate subgroup analyses to support labeling claims
- Missing or incomplete data from special populations such as pediatric or renal-impaired patients
- Inconsistencies between the clinical study reports and the integrated summaries
- Benefit-risk narratives that do not address the FDA’s specific concerns for the therapeutic area
How can companies reduce the risk of FDA submission rejection?
Companies can reduce the risk of FDA submission rejection by engaging with the FDA early and often, building a submission strategy around current guidance documents, and conducting rigorous internal quality reviews before filing. Proactive communication with the FDA through formal meeting requests is one of the most effective tools available — it allows sponsors to resolve ambiguities before they become grounds for rejection.
Early engagement should begin well before the pivotal study. Type B meetings, such as Pre-IND and End-of-Phase 2 meetings, give sponsors the opportunity to align with the FDA on trial design, CMC expectations, and the overall regulatory pathway. Companies that skip these interactions often discover late-stage misalignments that are expensive and time-consuming to correct. Learning more about our team and background can help you assess whether our experience matches your regulatory needs.
Internally, a structured pre-submission review that mirrors the FDA’s own assessment criteria can catch deficiencies before they reach the agency. This includes cross-functional reviews of the CMC section, statistical analysis plans, clinical summaries, and labeling. Consistency across all modules of the Common Technical Document (CTD) is essential — reviewers flag discrepancies between sections as indicators of broader quality problems in the submission.
What should companies do differently when resubmitting to the FDA?
When resubmitting to the FDA after a Complete Response Letter, companies should address every deficiency raised in the CRL completely and systematically, rather than responding only to the issues they find easiest to resolve. Partial responses are one of the most common reasons resubmissions fail — the FDA expects each point in the CRL to be directly addressed with new data, revised documentation, or a well-reasoned scientific argument.
Before preparing the resubmission, requesting a Type A meeting with the FDA to clarify the scope of required changes is often worthwhile. This is especially important when the CRL raises questions about clinical data, where the path forward may involve new studies, additional analyses, or a narrowed indication.
A strong resubmission also includes a response summary that maps each CRL comment to the specific section of the resubmission where it has been addressed. This makes the reviewer’s job easier and signals that the sponsor has engaged thoroughly with the FDA’s concerns. Companies that treat the resubmission as a collaborative process rather than a dispute tend to achieve better outcomes.
How Starodub supports companies navigating FDA submissions
We work with biopharmaceutical and medical device companies at every stage of the FDA submission process — from early regulatory strategy through resubmission after a Complete Response Letter. Our team brings hands-on experience with CMC documentation, clinical data packages, and regulatory operations, helping clients build submissions that are complete, consistent, and aligned with current FDA expectations.
Specifically, we help companies by:
- Developing regulatory strategies and submission roadmaps tailored to the product type and indication
- Reviewing and strengthening CMC sections to address common deficiency patterns before filing
- Preparing for and supporting FDA meetings, including Pre-IND, End-of-Phase 2, and Type A meetings
- Conducting pre-submission gap analyses to identify weaknesses across all CTD modules
- Preparing structured, complete responses to Complete Response Letters
- Providing regulatory operations support to ensure eCTD compliance and submission quality
Whether you are preparing a first submission or recovering from a rejection, our team is ready to help you move forward with confidence. Contact Starodub today to discuss your regulatory submission needs and find out how we can support your path to FDA approval.
Related Articles
- What is the difference between a CTA and IND submission?
- What is the ICH guideline?
- What regulatory changes are expected in 2026?
- What are the main types of medical device regulations worldwide?
- What are the benefits of ISO 13485 certification?
This content was generated with the help of AI and it may contain mistakes
